Searches , social queries for BUROSUMAB
Search references for BUROSUMAB. Phrases containing BUROSUMAB
See searches and references containing BUROSUMAB!
Search references for BUROSUMAB. Phrases containing BUROSUMAB
See searches and references containing BUROSUMAB!BUROSUMAB
Monoclonal antibody designed to treat X-linked hypophosphatemia
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia
Burosumab
American biopharmaceutical company
Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and
Ultragenyx
Drug class
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Anti-amyloid_antibodies
X-linked dominant disorder that causes rickets
for this condition, called burosumab. It was then licensed by the US Food and Drug Administration in June 2018 Burosumab is shown to target the major
X-linked_hypophosphatemia
Tricyclic antidepressant
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Amitriptyline
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Lecanemab
Combination drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Pertuzumab/trastuzumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tesevatinib
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Trevogrumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Refanezumab
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Donanemab
Sex-specific patterns of inheritance
included phosphate supplements and active vitamin D analogs. More recently, burosumab, a monoclonal antibody that targets FGF23, has been approved and shown
Sex_linkage
Experimental monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Prasinezumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Abelacimab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bedinvetmab
Medication for treatment of non-small-cell lung cancer
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erlotinib
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Idarucizumab
Medical condition
hypophosphataemia treated with a human monoclonal antibody against FGF23 called burosumab improved significantly compared to conventional therapy. "Entry - #193100
Autosomal dominant hypophosphatemic rickets
Autosomal_dominant_hypophosphatemic_rickets
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
RAMP1
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Lenvatinib
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bimagrumab
Cancer medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Sunitinib
Drugs that inhibit α-synuclein
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Anti-α-synuclein_drug
Mammalian protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Adrenomedullin
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Capmatinib
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Evolocumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Bosutinib
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Romosozumab
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erythropoietin_receptor
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tropomyosin_receptor_kinase_A
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Emicizumab
Veterinary medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Relfovetmab
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bevacizumab
Protein that stimulates red blood cell production
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erythropoietin
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Aducanumab
Primary male sex hormone
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Testosterone
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Marstacimab
Pharmaceutical biological monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Fremanezumab
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Erenumab
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Caplacizumab
Antibodies from clones of the same blood cell
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Monoclonal_antibody
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dehydroepiandrosterone
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Concizumab
Corticosteroid medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dexamethasone
Antibodies from non-human species made nearly identical to human ones
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Humanized_antibody
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Ponezumab
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Brain-derived neurotrophic factor
Brain-derived_neurotrophic_factor
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Alirocumab
Protein or other substance that stimulates cellular proliferation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Growth_factor
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Repotrectinib
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Insulin-like_growth_factor_1
Mammalian protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
HER2
Class of compounds
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
C-Met_inhibitor
Human monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Denosumab
Medical condition
treatments, hence minimising its impact on the child.[citation needed] Burosumab injection Drug therapy for maintaining normal calcium and phosphate levels
Phosphate_diabetes
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_B3
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
EPH_receptor_A1
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_A3
Group of signal transduction pathways involved in embryonic development
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Wnt_signaling_pathway
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Neuregulin_2
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Imatinib
Class of enzymes
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Receptor_tyrosine_kinase
Transmembrane receptors involved in cellular adhesion and signalling
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Integrin
TrkA and TrkB positive modulator
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
ACD856
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
GFRA3
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_A4
Veterinary medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Izenivetmab
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Filgrastim
Transmembrane protein
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Epidermal growth factor receptor
Epidermal_growth_factor_receptor
Medication which blocks growth of blood vessels
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Anti-VEGF
Anti-cancer medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dabrafenib
age-related macular degeneration Brontictuzumab mab humanized Notch 1 cancer Burosumab Crysvita mab human FGF 23 Y X-linked hypophosphatemia Cabiralizumab mab
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Signaling glycoprotein regulating cell proliferation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Platelet-derived growth factor
Platelet-derived_growth_factor
Family of biomolecules
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Neurotrophic_factors
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
EPH_receptor_A2
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Lenograstim
Pharmaceutical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Abciximab
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Trastuzumab_deruxtecan
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Opicinumab
Drug typically used in cancer treatment
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tyrosine_kinase_inhibitor
Protein-coding gene in mammals
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fibroblast_growth_factor_21
Family of proteins
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Neurotrophin
Protein that stimulates cell division and differentiation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Epidermal_growth_factor
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Galcanezumab
Medication for macular degeneration
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Faricimab
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Ranibizumab
Targeted cancer drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Vemurafenib
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Trastuzumab
Pharmaceutical drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Cetuximab
Family of proteins involved in anatomical development
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fibroblast_growth_factor
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fruquintinib
Chemical compound, used as a medication to treat lung cancer
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Osimertinib
Peptide hormone
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Insulin
Human protein-coding gene
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Platelet-derived growth factor receptor A
Platelet-derived_growth_factor_receptor_A
Class of drugs used to treat malignant tumors
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Antineoplastic
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
FMS-like tyrosine kinase 3 ligand
FMS-like_tyrosine_kinase_3_ligand
Monoclonal antibody medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Solanezumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Eptinezumab
Cancer medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Lapatinib
Experimental drug for neurodegenerative disorders
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Cerebrolysin
travel, tourism, insurance
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
travel, tourism, insurance